In a large proportion of familial and sporadic cases of Hirschsprung disease (HSCR) mutations in the RET (rearranged during transfection) protooncogene have been described. We have investigated the structure of the RET gene promoter and have analysed a region of approximately 1000 nucleotides in its promoter and 5'-upstream segments for the occurrence of 5-methyldeoxycytidine (5-mC) residues by using the bisul®te protocol of the genomic sequencing method. With an estimated sensitivity of about 93% of this technique, not a single 5-mC residue could be detected in the control region of a gene that seems to be silenced or exhibit low activity in many adult tissues. In these experiments, the DNAs of peripheral white blood cells (PWBC) from four healthy individuals, from seven patients with familial HSCR, as well as DNAs from dierent human tissues and from a human embryonic kidney (HEK) cell line have been included. In a DNA segment starting 790 nucleotides upstream of the transcriptional start site of the RET gene, a few 5-mC residues have been identi®ed. This region possibly constitutes the transition site from an unmethylated promoter to a more extensively methylated region in the human genome. The data presented are remarkable in that a highly 5'-CG-3'-enriched segment of the human genome with 49 5'-CG-3' dinucleotide pairs in 400 bp within the putative promoter region is completely devoid of 5-mC residues, although this control region is not actively transcribed in most adult human tissues. By hybridization of a PCR-ampli®ed RET protooncogene cDNA probe harboring exons 9 ± 15 to a membrane (Clontech) containing poly-A selected RNAs from 50 dierent human tissues, weak RET protooncogene expression in many of the neural cell derived tissues has been detected. RNAs extracted from many other human tissues do not share sequence homologies to this
Introduction
The human RET protooncogene is controlled by a promoter harboring several transcription factor binding sites (Itoh et al., 1992) , such as four tandemly repeated GC-boxes (Dynan and Tjian, 1985) , an ETF binding site (Kageyama et al., 1989) and Sp1 and AP-2 binding sites. Most of these sites are located within the 5'-CpG-3'-rich region in proximity to the transcriptional start site. In a region of approximately 900 base pairs, 95 5'-CG-3' dinucleotide pairs are found of which the majority are located within the putative promoter segment. Sequence-speci®c promoter methylation is frequently responsible for the long-term inactivation of eukaryotic genes (Doer¯er, 1983) . During embryogenesis, RET protooncogene expression is regulated in temporally and spatially strictly de®ned patterns (Pachnis et al., 1993; Avantaggiato et al., 1994; Schuchardt et al., 1994 Schuchardt et al., , 1995 Tsuzuki et al., 1995) . In most neural crest-derived tissues, RET protooncogene expression can be detected during embryogenesis. In the kidney and the urogenital systems, the RET gene is transcribed only at certain times during development. In most adult tissues the level of RET expression is very low, mRNA can be detected only in the adrenal medulla and in the cerebellum (Takaya et al., 1996) . Expression of the RET protooncogene has been analysed in tumor tissues like neuroblastoma, papillary thyroid carcinoma (PTC) (Bongarzone et al., 1994) or medullary thyroid carcinoma (MTC, FMTC) in MEN2A patients. Some neuroblastoma cell lines overexpress the RET protooncogene (Ikeda et al., 1990; Tahira et al., 1991) , while most other human cell lines analysed in culture show weak or no expression.
Hirschsprung disease (HSCR) (McKusick 249200) presumably results from an impaired development of neural crest-derived neurons of the enteric ganglia during the aected individuals' ontogenetic development. Frequency is one in 5000 newborns with an as yet unexplained predominance of 3.75-fold among male individuals (Bodian and Carter, 1963; Okamoto and Ueda, 1967; Goldberg, 1984; Badner et al., 1990 ; for a recent review see Passarge, 1997) . Extensive studies on the genetic origin of this congenital disorder have identi®ed several genes i.e. the RET protooncogene (10q11.2), the gene for the endothelin-B receptor (EDNRB) (13q22), glial cell line derived neurotrophic factor GDNF (5p12-13.1), endothelin 3 (EDN3) (20q13.2), and possibly others to be involved in the occurrence of the familial form of HSCR (Puenberger et al., 1994; Durbec et al., 1996; Hofstra et al., 1996; Trupp et al., 1996) . The major susceptibility gene for the autosomal dominant form of HSCR appears to be the RET protooncogene (Martucciello et al., 1991; Puliti et al., 1993; Lyonnet et al., 1994) .
We have studied the transcriptional activity of the RET gene in healthy and HSCR disease individuals and have investigated the methylation status of the RET gene promoter in the same individuals. This very 5'-CG-3'-rich promoter is transcriptionally inactive in many, though not all, human tissues. Nevertheless, in the promoter plus the 5'-upstream regions of the RET gene, not a single 5-mC residue has been detected by applying the highly sensitive bisul®te protocol of the genomic sequencing procedure.
Results
On the structure of the promoter of the human RET protooncogene
The promoter region of the RET protooncogene (Takahashi et al., 1985; Itoh et al., 1992) is CG-rich (476%) with a 5'-CG-3' score of 0.93 (GardinerGarden and Frommer 1987) . A 6.3 kbp XhoI (X) ± BamHI (B) fragment of the RET gene (Figure 1a ,b) was subcloned into pBKSII (Stratagene). The nucleotide sequence of the upstream regulatory segment (p6.3 clone) starting at position 75073 relative to the +1 transcriptional start site (Itoh et al., 1992) was determined (Patrone et al., 1997 ; GenBank AF032124) in order to localize suitable 5'-CG-3' regions for the application of the genomic sequencing protocol. The nucleotide sequence is presented in Figure 2 . The schemes in Figure 1 illustrate relevant parts of the restriction map, and a survey of the 5'-CG-3' dinucleotides, HpaII and HhaI sites (vertical lines in Figure 1b ) in the promoter and 5'-upstream sequence of the RET gene. The two 5'-CG-3'-rich regions I and II, that have been further investigated by genomic sequencing, are designated as shaded areas in Figure 1b . The locations of individual primers used in the genomic sequencing reactions are listed in Table 1 . In the analysed sequence of 900 nucleotides immediately upstream of the transcriptional start site of the RET gene, 95 5'-CG-3' dinucleotides are apparent. Upstream of this cluster, only 75 5'-CG-3' sequences are found in a stretch of 4300 nucleotide pairs.
Genomic sequencing: methylation analyses by the bisul®te protocol This previously described method (Frommer et al., 1992; Clark et al., 1994) has been adapted in our laboratory and tested for its reliability in an earlier report (Zeschnigk et al., 1997) . The following additional critical control experiments to assess the Figure 1 Physical map of the promoter region of the RET protooncogene. (a) Chromosomal location of the RET protooncogene at 10q11.2¯anked by the microsatellite markers D10S141 and s-TCL2 (Larimore et al., 1993) . The cosmid clone R1 (Pasini et al., 1995) of approximately 50 kbp was used to obtain the 6.3 kbp Xho (X)-BamHI (B) fragment comprising the RET promoter region and part of exon 1. E -EcoRI sites. (b) SmaI (Sm) and SacII (S) restriction map of the 6.3 kbp fragment. The locations of the putative promoter region and of exon 1 are indicated at the bottom of the graph. The positions of all 5'-CG-3' dinucleotides, HhaI (5'-GCGC-3') and HpaII (5'-CCGG-3') sites are designated by j. The transcriptional start site marked as +1 has been determined earlier (Itoh et al., 1992) . The shaded regions I and II illustrate the sequences analysed with the bisul®te method, ampli®ed by PCR, cloned and genomically sequenced. The two analysed regions are¯anked by the PCR primers listed in Table 1 . The shaded SmaI fragment designated 2.9 kbp probe has been used for hybridization in the experiment shown in Figure 4 reliability of the bisul®te conversion in the RET promoter sequence have now been performed.
(i) The plasmid p6.3-cloned promoter sequence of the RET protooncogene has been left unmethylated, has been mock methylated with M-HpaII DNAmethyltransferase in the absence of S-adenosylmethionine (SAM), or has been premethylated by using the DNA methyltransferase M-HhaI (5'-GCGC-3'), M-HpaII (5'-CCGG-3') or M-SssI (5'-CG-3') as detailed elsewhere (Zeschnigk et al., 1997) . The dierent methylation patterns determined after in vitro premethylation reveal the presence of 5-mC (®lled squares) at the expected sites in promoter region II ( Figure 3a ). Based on the results of these control experiments, we Figure 2 Nucleotide sequence of part of the RET promoter segment, between nucleotides 75076 and +226 in the cloned XbaI ± BamHI fragment as determined by the dideoxy chain termination protocol (Sanger et al., 1977) in an ABI 377A or 373A automated sequencer. EMBL accession number AF032124. The 5'-CG-3' dinucleotides that have been analysed by the bisul®te method of genomic sequencing are printed in bold letters and underlined. The transcriptional start site (?) and the beginning of exon 1 with the amino acid sequence (shaded) are also indicated. The sequence overlaps the previously described promoter region (Takahashi et al., 1985; Itoh et al., 1992) and diers in a few nucleotides from the published data recognize the bisul®te protocol to reveal 93% of the methylated sequences. (ii) Possible inadvertent contaminations of the genomic human DNA with traces of unmethylated p6.3 plasmid could have been detected as demonstrated by propagating all plasmids or cosmids in bacterial strains, such as XL1BlueMRF' (Stratagene). Its dcm + methylation system methylates the sequence 5'-CCNGG-3' at the C-residue neighboring N. We never found methylated 5'CCNGG-3' sites in genomic human DNA samples, and thus con®rmed their purity. Control plasmids were methylated at this site. (iii) We have redetermined the methylation patterns in the DNA from a Prader-Willi patient and a control proband in the SNRPN segment of the Prader-Willi region located on human chromosome 15q11-13 and reproduced the results presented earlier (Zeschnigk et al., 1997) .
We conclude that the previously established genomic sequencing protocol using bisul®te in the C to T conversion reaction of all C-residues, except the methylated ones, in a nucleotide sequence can also be reliably applied to the analysis of the promoter of the RET protooncogene.
The pictograms in Figure 3b and c summarize the results of the genomic sequencing experiments over the entire promoter region of the RET gene in 10 independently isolated and sequenced clones. In the schematic presentation chosen, open squares designate T-residues, indicative of C-residues in the original nucleotide sequence prior to the bisul®te treatment by the genomic sequencing reactions, ®lled squares represent bisul®te-resistant 5-mC-residues in the original nucleotide sequence. Apart from randomly distributed ®lled squares in singular clones, which we interpret as PCR artifacts, evidence for the presence of 5-mC residues in this sequence has not been obtained. Thus, surprisingly, the entire promoter region is devoid of 5-mC in all DNA samples investigated, including DNA samples from peripheral white blood cells of healthy individuals and HSCR patients. Moreover, DNAs from ®ve healthy individuals and seven HSCR patients, from a human embryonic kidney cell line and several human tissues yield the same negative results (Table 2 ). It is concluded that the transcriptionally often inactivated RET protooncogene promoter lacks 5-mC residues in 900 nucleotide pairs 5'-upstream of the site of initiation of transcription.
Transition to a more 5'-upstream located, methylated region
The nucleotide sequence immediately upstream of the 900 nucleotide pair segment investigated by genomic Figure 2 . Nucleotide sequences of all primers used in the genomic sequencing analyses. For each region, both sets of primers used in nested PCR are shown. Top primers are located 5' of the analysed region, bottom primers at the 3' end. In some primer sequences, a 1:1 mixture of C and T or, on the bottom strand, of A and G has been used, at positions that contain 5'-CG-3' dinucleotides in the primer region, to achieve optimal annealing of the primers The presence of 5-mC-residues in the two analysed 5'-and promoter regions of the RET protooncogene in DNA isolated from peripheral white blood cells (PWBC) was tested in DNA from healthy control individuals (b) or from HSCR patients (c). For each type of DNA sample, 10 independent clones (horizontal lanes of squares) were sequenced and analysed. The ®lled squares indicate the occurrence of an unconverted cytosine residue which has been derived from a 5-mC-residue in the original DNA sequence prior to bisul®te treatment. Each vertical column of squares presents the data for one 5'-CG-3' dinucleotide in the promoter sequence. For each patient, healthy control individual or tissue DNA, at least 10 independent clones have been analysed. Only part of the data has been reproduced here; all data have been summarized in Table 2 sequencing contains only 75 5'-CG-3' sequences among about 4300 nucleotide pairs. By dint of the reduced number of 5'-CG-3' dinucleotides in the segment between nt72000 and nt74500 ( Figure 1b ) and the scarcity of HpaII (5'-CCGG-3') and HhaI (5'-GCGC-3') restriction sites, we decided to investigate the methylation status of that area by restriction analyses with HpaII or HhaI followed by Southern blotting (Southern, 1975) . A hybridization probe, a puri®ed 2.9 kb SmaI fragment of the p6.3 clone (Figure 1b , shaded segment) comprising the area of interest was used. The restriction pattern of MspI (M) (5'-CCGG-3') was used as reference because of the enzyme's ability to cut even methylated DNA at the recognition sites. The HpaII (H) and HhaI (Hh) patterns of this 5'-upstream DNA segment reveal intensely methylated restriction sites (Figure 4) . Due to the abundance of 5'-CG-3' sequences in the analysed area, some cross hybridization to unrelated parts of the genomic DNA with a smeary appearance of the blots have to be tolerated. We conclude that the genomic region starting at about nucleotide72000 and extending to about74500 nucleotide pairs 5'-upstream of the RET promoter is methylated at least in some of the 5'-CCGG-3' and 5'-GCGC-3' sequences. This genome section possibly represents the site of transition from the completely unmethylated RET promoter region to a more densely methylated area.
The activity of the RET protooncogene promoter is inhibited by DNA methylation in transfection and transient transcription experiments
The complete absence of 5-mC in the RET gene regulatory region prompted us to investigate whether the transcriptional activity of the RET gene could be aected at all, e.g. by in vitro methylation. The genomic segment between nucleotides73092 to +53 contains multiple 5'-CG-3' sequences that can be premethylated in vitro by the M-HpaII, M-HhaI or the M-SssI DNA-methyltransferase as shown previously for several viral promoters (Kruczek and Doer¯er, 1983; Langner et al., 1984; Weisshaar et al., 1988; Munnes et al., 1995) . The CAT (chloramphenicol acetyltransferase) gene has been chosen as activity indicator (Figure 5) , and the neuroblastoma cell line CHP134 as a suitable recipient for transfection experiments. This cell line has been reported to be able to express the RET protooncogene (Bunone et al., 1995) . The RET promoter-CAT reporter gene construct has been methylated with M-HhaI (5'-GCGC-3'), M-HpaII (5'-CCGG-3') or the M-SssI (5'-CG-3') DNA-methyltransferase. Mock-methylation experiments have been performed with M-HhaI DNAmethyltransferase in the absence of SAM. The constructs (map in Figure 5 ) have been transfected into CHP134 cells and CAT activity has been measured at 48 h posttransfection. All transfections have been Among the unaected probands, males and females have been analysed. The methylation status`unmethylated' derives from at least 10 independent clones that all show absence of methylation. The status`rarely methylated' refers to a few methylated 5'-CG-3' dinucleotides in position 7780 nt. as shown for region I in Figure  3b and c performed as cotransfections with the b-galactosidase expressing vector pCMV-b-gal to normalize CAT reactions for transfection eciency. The RET protooncogene promoter exhibits activity levels in CHP134 cells comparable to those of the early SV40 promoter present in the SV40 promoter-CAT gene construct (pSVCAT) used as control ( Figure 5 ). Mock-methylation does not signi®cantly alter the promoter activity, HpaII methylation reduces promoter activity slightly, while SssI methylation completely abolishes it. The HhaI methylated construct showed probably insigni®-cantly enhanced activity. Figure 5 summarizes the results of ®ve dierent experiments.
We conclude that the human RET promoter is sensitive to DNA methylation at 5'-CG-3' sites in vitro. Transcriptional regulation of the RET gene mediated by C-methylation is therefore possible and might be operative during development as in many other developmentally regulated genes (Constantinides et al., 1977; for review Cedar and Razin, 1990) .
In several adult human tissues and human cell lines the RET protooncogene is not or only weakly transcribed
It has been reported that the RET gene is not transcribed in adult human tissues but is expressed during embryonic development in a variety of vertebrates (Pachnis et al., 1993; Avantaggiato et al., 1994; Schuchardt et al., 1995) . We have investigated poly A-selected RNA samples extracted from 50 human tissues. These RNAs have been immobilized in separate dots on a membrane (Clontech, Human RNA Master blot) and hybridized to a 32 P-labeled PCR cDNA fragment corresponding to exons 9 ± 15 of the RET protooncogene. Hybridization signals have been obtained after a 16 h exposure in most neural crestderived tissues and in brain (Figure 6 ). The strong signal in RNA from substantia nigra (Figure 6 , panel B3) may be due to the high density of motoneurons in this tissue. Compared to the weak signal seen with total human control DNA (Figure 6a, panel H8) , most of the faint signals obtained with RNAs from other tissues can be considered evidence for very low, if any, activity. RNAs from all other sources lack sequences homologous to the human RET protooncogene as detectable by Northern blot hybridization. These results are similar to previously published work (Schuchardt et al., 1995; Takaya et al., 1996) . Apparently, the RET gene is not eciently transcribed in most adult human tissues.
Discussion
Mutations in the human RET protooncogene have been implicated in the causation of familial and sporadic cases of HSCR (AttieÂ et al., 1995) . These mutations are frequently associated with autosomal dominant inheritance of the disease in families Romeo et al., 1994) . It is also of interest that certain mutations occur in families aicted by both HSCR and MEN2a (Kambouris et Figure 5 The RET promoter can be inactivated by sequence-speci®c DNA methylation. Top: The bar graphs summarize the results of ®ve dierent experiments in which CAT activities have been measured after the transfection of unmethylated, mock-methylated or dierently methylated RET promoter-CAT gene constructs into the human neuroblastoma cell line CHP134. The ordinate refers to relative activities. Experimental details have been described in the text. Bottom: Restriction map of the RET promoter region with the locations of a BglII and MaeII restriction site, which have been used for subcloning a *3 kbp fragment in front of the chloramphenicol-acetyl-transferase (CAT) reporter gene. This BglII ± MaeII fragment contains the 5' and promoter regions of the RET gene found to be unmethylated in all analysed DNA samples (see Figure 3) . Several SmaI sites are also indicated al., 1996). The RET protooncogene is transcriptionally active during certain stages of embryonic development, but frequently silenced in many adult human tissues and human cell lines in culture. It has therefore been worth investigating to what extent the promoter of the long-term inactivated RET protooncogene is methylated. When complemented by appropriate control experiments with in vitro speci®cally premethylated DNA constructs (Figure 3a) and when based on the sequencing of a sucient number of cloned PCR products, the bisul®te protocol of the genomic sequencing method (Frommer et al., 1992) has proved a reliable and ecient method to determine DNA methylation patterns in the human genome (Clark et al., 1994; Zeschnigk et al., 1997 ; this study).
The putative RET promoter segment carries 49 5'-CG-3' dinucleotides in a stretch of some 400 nucleotide pairs. This segment can be considered a 5'-CG-3' rich promoter. Our analyses on the occurrence of 5-mC residues in a region of about 900 nucleotide pairs in the RET promoter plus 5'-upstream regions with the genomic sequencing method have revealed the total absence of this modi®ed nucleotide (Figure 3b,c; Table 2 ). This result pertained to the DNAs from several human tissues of healthy and HSCR individuals and to the DNA from human cell lines. In a series of studies on DNA methylation patterns in the human genome performed in our laboratory (Kochanek et al., 1990 (Kochanek et al., , 1993 Behn-Krappa and Doer¯er, 1993; Zeschnigk et al., 1997) , the RET gene promoter is the ®rst DNA region of considerable size that completely lacks 5-mC residues. This ®nding is particularly remarkable in that this DNA segment appears to be frequently silenced (Ikeda et al., 1990; Nagao et al., 1990; Szentirmay et al., 1990) . Of course, it is unknown whether the RET gene might be occasionally activated under certain conditions. Nevertheless, the long-term inactivation of this gene might be independent of a sequence-speci®c methylation pattern. Other conventionally discussed factors, like proteins bound to speci®c promoter motifs, e.g. AP2, Sp1 or ETF, or a certain structure of the promoter within the bounds of a higher chromatin order, could be contributing elements of maintaining the quiescent state of this regulatory domain. Transcription factor binding sites Krox-20 or -24 (Patrone et al., 1997) may also play a role. It is a matter of conjecture whether the high 5'-CG-3' density in the region itself contributes to the structural characteristics of this domain.
With this remarkable promoter structure, it has been important to assess experimentally whether this promoter could be inactivated by sequence-speci®c methylation in transfection and transient expression experiments. In similar studies on the activity and methylation-mediated inactivation of viral promoters, we and others have developed this technique more than a decade ago (e.g., Keshet et al., 1985; Kruczek and Doer¯er, 1983; Langner et al., 1984; Weisshaar et al., 1988; Munnes et al., 1995) . The promoter, whose sensitivity towards sequence-speci®c methylation had to be challenged, has been frequently fused to the procaryotic CAT gene (Gorman et al., 1982) . The relevant experiments performed with a RET promoter-CAT gene construct ( Figure 5 ) demonstrate that the RET gene promoter activity can be inhibited by 5'-CCGG-3' (M-HpaII) methylation, but can be completely silenced by 5'-CG-3' (M-SssI) methylation. Hence, the RET promoter is capable of responding to C-residue modi®cations, although this instrument of long-term silencing appears not to be used in the human tissues and cell lines investigated.
The absence of 5-mC residues in the RET promoter has been noted in the DNA from tissues of both healthy and HSCR individuals (Figure 3b ,c, Table 2 ). It is also worth noting that in a segment of genomic DNA starting at about72000 nucleotides 5'-upstream of the transcriptional start site of the RET protooncogene, 5-mC residues can be detected in 5'-CCGG-3' (HpaII) and 5'-GCGC-3' (HhaI) sites. Could this region represent a transitory segment of human DNA between an area devoid of 5-mC and a more completely methylated domain in the human genome.
The data on the transcription of the RET protooncogene in dierent human tissues reveal low to moderate levels of RET-speci®c polyadenylated RNA in cerebellum, cerebral cortex, medulla oblongata, occipital lobe, substantia nigra, temporal lobe, thalamus, subthalamic nucleus, spinal cord, and adrenal gland ( Figure 6 ). Thus, most neural tissues show some transcription of the RET gene in the adult. There are very weak signals with RNAs from a few additional tissues. We pursue the possibility that transcription of the RET protooncogene may not be completely and permanently silenced. It is conceivable that at certain times, even in adult life, RET transcripts may be required, possibly only in certain cell types of organs such as the liver or the prostate. This concept is consistent with the very low, if any, transcription in some of these organs. Moreover, this notion would explain the lack of promoter methylation since that modi®cation is usually used in long-term promoter inactivation which is inadvertent for genes whose function is occasionally required.
Material and methods

Patients
The Hirschsprung disease (HSCR) patients whose DNA was investigated in this paper were phenotypically characterized. Linkage studies implied involvement of the RET locus in these families. The molecular analyses of the DNA samples were described in detail elsewhere (Ceccherini et al., 1993 .
Cell lines
The DNA of a human embryonic kidney (HEK) cell line was analysed with the method of genomic sequencing. In tests for the transient expression of several dierent RET promoter-CAT gene constructs, a RET gene-expressing human neuroblastoma cell line CHP 134 (Bunone et al., 1995) was transfected. All cell lines were grown in Dulbecco minimal essential medium (DMEM) supplemented with antibiotics and 10% fetal calf serum (FCS).
DNA preparations, plasmids and cosmids
Genomic DNAs from peripheral white blood cells and the HEK cell line were prepared as described elsewhere (Kunkel et al., 1977; Kochanek et al., 1993, respectively) . A 6.3 kb XhoI ± BamHI fragment from the 3'-part of the cosmid RI (Pasini et al., 1995) including the putative promoter and exon 1 of the RET protooncogene was subcloned into pBluescript II (Stratagene). Maps of the plasmids, cosmids or subclones used were presented in Figures 1 and 5 .
Determination of the nucleotide sequence of the clone p6.3 and of the cloned PCR products The p6.3 genomic fragment containing the 5'-upstream region of the RET gene was sequenced as described elsewhere (Patrone et al., 1997) . The nucleotide sequences of the cloned PCR products generated by the bisul®te protocol of genomic sequencing experiments were determined by using the sequencing primers SP6, T3 and a 19 nucleotide universal primer in the automated Applied Biosystems DNA Sequencer 373A or 377A.
Genomic sequencing by the bisul®te protocol
Bisul®te treatment (Frommer et al., 1992; Clark et al., 1994) of genomic DNA (5 mg) and plasmid or cosmid DNA (10 pg mixed with 5 mg unspeci®c DNA) was performed after cleavage with the restriction enzyme EcoRI or BamHI exactly as described earlier (Zeschnigk et al., 1997) . PCR was performed in a Perkin-Elmer 480 thermocycler under the following conditions: 1 cycle for 5 min at 948C, 30 cycles for 1 min at 948C ± 1 min at 558C ± 2 min at 728C, followed by 1 cycle for 3 min at 728C.
Analysis of human tissue RNAs for the presence of RET gene-speci®c signals
PCR products have been ampli®ed from 50 pg of cloned RET protooncogene cDNA under the following conditions: 1.8 mM Mg 2+ , 50 mM KCl, 10 mM Tris-HCl, pH 9.0, 0.1% Triton X-100, 1.2 mM of each primer F: CACTGCGATGTTGTGGAGAACC R: TCCGAAATCTTCATCTTCCGC.
Cycle conditions (35 cycles) were 30 s at 958C, 30 s at 648C, 45 s at 728C (Perkin-Elmer PE9600). Subsequently, the PCR fragments were puri®ed by electrophoresis on a 2% agarose gel, extracted with QiaSpin gel extraction columns, and 32 P-labeled by standard procedures for 16 h at 378C. This probe was hybridized to RNAs on a RNA-Master Blot (Clontech # 7770-1) at 688C for 16 h. The RNA membrane had been precoated with salmon sperm DNA. After hybridization, the membrane was washed three times in 26SSC, 1% SDS, each for 10 min at 688C. After control exposure, the ®lter was washed again in 0.16SSC, 0.5% SDS for 10 min at 688C.
In vitro premethylation of the p6.3 plasmid DNA and of the RET gene promoter-CAT gene constructs
As an internal control for the bisul®te treatment of DNA, 10 pg of M-HpaII, M-HhaI or M-SssI premethylated or mock-methylated p6.3 plasmid was mixed with 5 mg herring sperm DNA and used in the genomic sequencing reactions. The in vitro methylation was performed by using 10 U of one of the DNA-methyltransferases per 1 mg DNA and by incubation for 16 h at 378C as described earlier (Munnes et al., 1995) . The plasmids used in transfection and transient transcription experiments were incubated with 4 U of DNA-methyltransferases per mg DNA. Complete premethylation was ascertained by cleavage with the appropriate restriction endonucleases followed by polyacrylamide gel electrophoresis. For mock-methylation experiments, the methyldonor S-adenosylmethionine (SAM) was omitted.
Transfection and transient expression experiments using unmethylated, methylated or mock-methylated RET gene promoter-CAT gene constructs For transient expression experiments, we used the promoter construct pRET promoter-CAT gene containing the genomic region from73092 to +53 of the RET locus (Figure 2 ) in the promoter-less pCATBasic vector (Promega). The 6.3 kb XhoI ± BamHI fragment was partly cleaved with MaeII restriction endonuclease. A 5109 bp fragment comprising nucleotides75056 to +53 of the RET locus was isolated, cloned into the ClaI site of the pBluescript vector (Stratagene) and subsequently transferred into the XbaI ± HindIII site of the pCATBasic vector. pRET promoter-CAT is a deletion clone derived fom this longer promoter construct by HindIII ± BglII cleavage, blunting and subsequent ligation. Details of the transfection experiments and their evaluation were described by Patrone et al. (1997) .
